FDA Approval Of Xarelto Bodes Well For Drug’s Future Expansion
The July 1 approval of Johnson & Johnson’s novel anticoagulant Xarelto for prevention of deep vein thrombosis is an important step for J&J and its ex-U.S. partner Bayer AG as they gear up to play in the highly promising but increasingly complicated world of novel anticoagulants.
You may also be interested in...
Xarelto, Pradaxa Difficult To Separate After Positive NICE Final Guidance
Bayer’s Xarelto has made it into the NHS in England after its NICE recommendation went unchallenged, prompting a head to head battle with Boehringer Ingelheim’s Pradaxa.
Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation and at risk of stroke. Results are due in 2020.
Xarelto Filing Puts It Out Ahead In Venous Thromboembolism
Though other novel anticoagulants are in development for treatment and prevention of venous thromboembolism, Janssen and its partner Bayer are hoping Xarelto will be coming out ahead.